Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin in advanced uterine and ovarian carcinosarcoma
NCT02993705Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in ovarian carcinosarcoma (OCS) and uterine carcinosarcoma (UCS), sponsored by Policlinico Gemelli. Primary endpoint: Objective Response Rate up to 3 years. Started Feb 2017; status: completed.
02
Drugs
trabectedin
03
Conditions
ovarian carcinosarcoma (OCS)uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT02993705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02993705.